|
| Publications [#79898] of Shelby Reed
Papers Published
- SD Reed, JI Radeva, KP Weinfurt, JJ McMurray, MA Pfeffer, EJ Velazquez, JS Allsbrook, LE Masselink, MA Sellers, RM Califf, KA Schulman, VALIANT Investigators, Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).,
American heart journal, vol. 150 no. 2
(August, 2005),
pp. 323-9, ISSN 1097-6744 [doi]
(last updated on 2013/07/01)
Abstract:
BACKGROUND: In a multinational clinical trial, valsartan was statistically not inferior to captopril in reducing mortality and cardiovascular morbidity after myocardial infarction (MI) in patients with signs of heart failure and/or left ventricular dysfunction. We conducted a prospective economic evaluation to compare within-trial resource use, costs, and quality of life in patients receiving valsartan, captopril, or both after MI. METHODS: We assigned country-specific unit costs to resource use data for 14703 patients and measured health-related quality of life in a subset of 4524 patients. We used the nonparametric bootstrap method to compare rates of resource use and costs, and a piecewise linear mixed-effects regression analysis to compare longitudinal measures of quality of life. RESULTS: There were no significant differences in rates of resource use between the valsartan and captopril groups. During an average follow-up of 2 years, total costs for patients receiving valsartan were significantly higher than for patients receiving captopril (USD 14103 vs USD 13038; 95% CI USD 369-USD 1875). The cost differential was caused primarily by the cost of the study medications (USD 1056 for valsartan vs USD 165 for captopril; 95% CI USD 867 to USD 912). Quality of life did not differ significantly between groups. CONCLUSIONS: For most patients at high risk after MI, the availability of generic captopril confers a cost advantage over valsartan because of lower medication costs. The difference will be smaller or nonexistent in settings where brand-name ACE inhibitors are prescribed.
Keywords:
Ambulatory Care • Angiotensin II Type 1 Receptor Blockers • Angiotensin-Converting Enzyme Inhibitors • Captopril • Drug Costs • Health Care Costs • Health Resources • Heart Failure • Hospital Costs • Hospitalization • Humans • Myocardial Infarction • Prospective Studies • Quality of Life • Tetrazoles • Valine • Ventricular Dysfunction, Left • World Health • analogs & derivatives* • complications • drug therapy • drug therapy* • economics • etiology • psychology • statistics & numerical data • therapeutic use • therapeutic use* • utilization • utilization*
|
